<code id='D31A67FE1F'></code><style id='D31A67FE1F'></style>
    • <acronym id='D31A67FE1F'></acronym>
      <center id='D31A67FE1F'><center id='D31A67FE1F'><tfoot id='D31A67FE1F'></tfoot></center><abbr id='D31A67FE1F'><dir id='D31A67FE1F'><tfoot id='D31A67FE1F'></tfoot><noframes id='D31A67FE1F'>

    • <optgroup id='D31A67FE1F'><strike id='D31A67FE1F'><sup id='D31A67FE1F'></sup></strike><code id='D31A67FE1F'></code></optgroup>
        1. <b id='D31A67FE1F'><label id='D31A67FE1F'><select id='D31A67FE1F'><dt id='D31A67FE1F'><span id='D31A67FE1F'></span></dt></select></label></b><u id='D31A67FE1F'></u>
          <i id='D31A67FE1F'><strike id='D31A67FE1F'><tt id='D31A67FE1F'><pre id='D31A67FE1F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:focus    - browse:1274
          Lung cancer under microscope — coverage from STAT
          Lung cancer Adobe

          CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

          Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

          advertisement

          Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge